Madrigal Pharmaceuticals
MDGL
91 hedge funds and large institutions have $471M invested in Madrigal Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 8 closing their positions.
475% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 8
291% more capital invested
Capital invested by funds: $120M → $471M (+$350M)
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
72% more funds holding
Funds holding: 53 → 91 (+38)
15.11% more ownership
Funds ownership: 21.39% → 36.5% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$31.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21.8M |
| 3 |
Jennison Associates
New York
|
+$11.7M |
| 4 |
PA
Perceptive Advisors
New York
|
+$10.8M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$8.68M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$4.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.77M |
| 4 |
Renaissance Technologies
New York
|
-$2.27M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.64M |
MDGL Hedge Fund Activity: Q4 2017 in Review
91 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2017, worth a combined $471M — up 291% from $120M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MDGL positions and 8 closed out — a net gain of 38 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $31.9M. The largest seller was Armistice Capital, cutting an estimated $8.68M.
- 91 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2017, up from 53 in Q3 2017.
- Funds reported $471M of Madrigal Pharmaceuticals stock for Q4 2017, up 291% quarter-over-quarter.
- 46 funds opened new Madrigal Pharmaceuticals positions in Q4 2017 and 8 closed out, a net change of +38 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2017 was Baker Bros. Advisors, an estimated $31.9M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2017 was Armistice Capital, an estimated $8.68M sold.
Based on aggregated 13F filings for Q4 2017.